ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0158 • ACR Convergence 2025

    Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)

    Lesley Jackson1, jerrod anzalone2, Rahima Begum3, Fazlur Rahman1, Namrata Singh4, Londyn Robinson5, Kaleb Michaud2, Kenneth Saag6, Jasvinder Singh7, Rena Patel1 and Maria I. ("Maio") Danila8, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Nebraska Medical Center, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, 4University of Washington, Bellevue, WA, 5University of Washington, Seattle, WA, 6The University of Alabama at Birmingham, Birmingham, AL, 7Baylor College of Medicine, Houston, TX, 8University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
  • Abstract Number: 0206 • ACR Convergence 2025

    Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies

    Nadia Emi Aikawa1, Julia Medeiros2, Sandra G Pasoto3, Ana C Medeiros-Ribeiro3, Luciana Parente Costa Seguro4, Ana Paula Luppino-Assad5, Emily Figueiredo Neves Yuki6, Lissiane Guedes7, Clovis Artur Silva8 and Eloisa Bonfa4, 1Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 4Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, 6Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, 8University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
  • Abstract Number: 0235 • ACR Convergence 2025

    Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years

    ZAUHA FAWAD MEMON1, Sibgha Fawad Memon2, Matia Fawad Memon2, REHAN ISHAQUE3, AHMAD SANAN4 and MUHAMMAD MUGHEES5, 1Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, 2Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Pakistan, 3LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, Jam Shoro, Sindh, Pakistan, 4KHYBER MEDICAL COLLEGE, Peshawer, Pakistan, 5Bahria University health Sciences, KARACHI, Pakistan

    Background/Purpose: Inflammatory polyarthropathy (IPA) is a group of chronic autoimmune disorders, common among older adults and contribute significantly to systemic inflammation and cardiovascular risk .…
  • Abstract Number: 0230 • ACR Convergence 2025

    An Epic journey – Therapeutic Drug Monitoring at an Academic Center

    Puja Khanna1 and Michael Rice2, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Gastroenterology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
  • Abstract Number: 0132 • ACR Convergence 2025

    Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome

    Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)

    Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
  • Abstract Number: 0240 • ACR Convergence 2025

    Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features

    Amir Razmjou1, Alexandra Klomhaus2, David Kellner3, Meika Fang4, Michael Weisman5 and John FitzGerald3, 1UCLA / Veterans Affairs, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA, Los Angeles, CA, 4VA Greater Los Angeles/UCLA, Los Angeles, CA, 5Cedars-Sinai Medical Center, LOS ANGELES, CA

    Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the…
  • Abstract Number: 0270 • ACR Convergence 2025

    Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria

    Rafael Gálvez Sánchez1, Ivan Ferraz Amaro2, Fernando Lopez Gutierrez3, Javier Loricera4, Pablo Martínez Calabuig5, Jorge Juan Fragío Gil6, Roxana González Mazarí7, Cristina Hormigos Martín8, DALIFER FREITES9, Maria Rodríguez Laguna8, Patricia Moya Alvarado10, Marta López I Gómez11, Hector Corominas Macia10, Maite Silva Díaz12, Guillermo González Arribas12, Angel García Aparicio13, Judit Font-Urgelles14, Ivette Casafont Solé15, Elisabet Castaneda16, Carolina Merino Argumánez17, Raquel Zas Vaamonde18, Juan Molina Collada19, Sergio Rodríguez Montero20, Rafael Melero Gonzalez21, Eva Galíndez Agirregoikoa22, Andrea Hernández23, Lucia Pantoja Zarza24, Ignacio Braña Abascal25, Vega Jovaní26, Elia Valls Pascual27, Natalia Mena Vázquez28, ADELA MARIA GALLEGO FLORES29, Noelia Cabaleiro Raña30, Raúl Veroz González31, Mariano Andrés32, Santos Castañeda Sainz33 and Ricardo Blanco34, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 5Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, 6Hospital General Universitario, Valencia, Spain, 7Hospital General Universitario de Valencia, Reumatología, Valencia, Valencia, Spain, 8Hospital Clínico San Carlos, Reumatología, Madrid, Madrid, Spain, 9Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 10Hospital de Sant Pau, Reumatología, Barcelona, Barcelona, Spain, 11Hospital Universitario de Araba, Reumatología, Vitoria,, Vitoria, Spain, 12Complejo Hospitalario Universitario de A Coruña, Reumatología, A Coruña, Spain, 13Hospital Universitario de Toledo, Reumatología, Toledo, Toledo, Spain, 14Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 15Hospital German Trias i Pujol, Reumatología, Badalona, Badalona, Spain, 16Hospital Universitario Infanta Sofía, Reumatología, Madrid, Madrid, Spain, 17Hospital Universitario Puerta del Hierro, Reumatología, Madrid, Madrid, Spain, 18Hospital Universitario 12 de Octubre, Reumatología, Madrid, Madrid, Spain, 19Hospital General Universitario Gregorio Marañón, Reumatología, Madrid, Madrid, Spain, 20Hospital Universitario de Valme, Reumatología, Sevilla, Sevilla, Spain, 21Hospital Alvaro Cunqueiro, Reumatología, Vigo, Vigo, Spain, 22BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 23Hospital Universitario de Gran Canaria Dr Negrin, Reumatología, Palmas de Gran Canaria, Gran Canaria, Spain, 24Hospital General de Segovia, Reumatología, Segovia, Segovia, Spain, 25Hospital Universitario Central de Asturias, Reumatología, Oviedo, Oviedo, Spain, 26Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, 27Hospital General de Valencia, Reumatología, Valencia, Valencia, Spain, 28Hospital Regional Universitario de Málaga, Reumatología, Málaga, Malaga, Spain, 29Complejo Hospitalario don Benito Villanueva, Reumatología, Badajoz, Badajoz, Extremadura, Spain, 30Hospital Universitario Montecelo, Reumatología, Pontevedra, Pontevedra, Spain, 31Hospital de Mérida, Reumatología, Mérida, Mérida, Spain, 32Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Spain, 33Hospital Universitario La Princesa, Reumatología, Madrid Grupo de cooperación nacional de enfermedad relacionada con IgG4: Blanca García Magallón (Hospital Universitario Puerta del Hierro), Maite Odriozola Gil (Hospital Universitario de Valme), Cristina Arciniega (Hospital de Mérida), Maria Lourdes Mateo Soria (Hospital German Trias i Pujol), Santiago Muñoz (Hospital Universitario Infanta Sofía), Iñigo Jesús Rua Figueroa, (Hospital Universitario de Gran Canaria Dr Negrin), Sabela Fernández Aguado, (Hospital de Montecelo)., Madrid, Spain, 34Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by fibro-sclerosing inflammation, elevated serum and tissue IgG4 levels, and heterogeneous clinical manifestations. Several classification…
  • Abstract Number: 0181 • ACR Convergence 2025

    Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans

    Cherish Wilson1, Catherine Nasrallah2, Gary Tarasovsky3, Alicia Hamblin4, Asia Williams5, Broderick Flynn5, Bernard Ng6 and gabriela Schmajuk7, 1UCSF / SFVA, San Francisco, CA, 2University of California San Francisco (UCSF), San Francisco, CA, 3SFVA, San Francisco, 4UCSF, San Francisco, CA, 5Lexington VA, Lexington, 6Lexington VA, University of Washington, Seattle, 7University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Background/Purpose: Given the nationwide shortage of rheumatologists, particularly in rural areas, many Veterans Affairs (VA) facilities have struggled to hire or retain specialists, resulting in…
  • Abstract Number: 0159 • ACR Convergence 2025

    Prenatal and Early-Life Environmental Exposures in Juvenile-Onset Systemic Autoimmune Rheumatic Diseases

    Takuma Ohnishi1, Megan Zhao1, Min Shi2, Adam Schiffenbauer3, Sharon Jackson3, Anna Jansen1, Nastaran Bayat4, Payam Farhadi1, Christine Parks2, Clarice Weinberg2, Frederick Miller5 and Lisa Rider6, 1National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, 2National Institutes of Health/National Institute of Environmental Health Sciences, Research Triangle Park, NC, 3National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, 4National Institutes of Health/National Institute of Environmental Health Sciences, Gaithersburg, MD, 5National Institutes of Health/National Institute of Environmental Health Sciences, Chapel Hill, NC, 6National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD

    Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs), including juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc), are characterized…
  • Abstract Number: 0222 • ACR Convergence 2025

    Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey

    Isaac Smith1, Linda Tovar2, Michael Battistone2, Andrea Barker3, Bryant England4, Ankoor Shah5, Joshua Baker6, Katherine Wysham7, Beth Wallace8, Ted Mikuls4, Deanna Lazaro9, Pascale Schwab10, Paul Monach11, Gail Kerr12, Andreas Reimold13, Gary Kunkel2, Liron Caplan14, John Richards15, Aleksander Lenert16, Andrew Jones17, Maria I. ("Maio") Danila18, Brian Sauer19, Jorge Rojas20 and Grant Cannon21, 1Duke University Hospital, Durham, NC, 2Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA, Cottonwood Heights, UT, 4University of Nebraska Medical Center, Omaha, NE, 5Duke University, Durham, NC, 6University of Pennsylvania, Philadelphia, PA, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9VA New York Harbor Healthcare System, Brooklyn, NY, 10Oregon Health & Science University, Portland, OR, 11VA Boston Healthcare System, Boston, MA, 12Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 13Dallas VA Medical Center, Dallas, TX, 14University of Colorado, Denver, CO, 15Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 16Iowa Carver College of Medicine, Iowa City, IA, 17VA Saint Louis and Washington University, Saint Louis, 18University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 19Salt Lake City VA/University of Utah, Salt Lake City, UT, 20VA Puget Sound Health Care System, Seattle, WA, 21University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…
  • Abstract Number: 0255 • ACR Convergence 2025

    Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis

    Justin Riley Lam1, Emmanuel Otabor2, Laith Alomari2, Esteban Kosak Lopez2, Maxim Barnett2 and Shahrzad Abdollahi3, 1Albert Einstein Medical Center, Philadelphia, PA, 2Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, 3Jefferson Einstein Hospital, Philadelphia, PA

    Background/Purpose: Cannabis use has increased substantially in the past decades, with legalization expanding across the U.S. Despite its known therapeutic potential, the immunomodulatory effects of…
  • Abstract Number: 0188 • ACR Convergence 2025

    Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data

    Taylor Williamson1, Emily Shantz1, Susan Elliott1, Christine Sperling2, Karen H. Costenbader3 and May Choi4, 1University of Waterloo, Waterloo, Canada, 2None, Calgary, Canada, 3Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 4University of Calgary, Calgary, AB, Canada

    Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…
  • Abstract Number: 0211 • ACR Convergence 2025

    Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration

    Alexandra Do1, Lisa Matsumoto1, Cherish Wilson2, Gary Tarasovsky3, gabriela Schmajuk4 and Jennifer Barton5, 1Oregon Health and Science University, Portland, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, 4University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 5VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
  • Abstract Number: 0175 • ACR Convergence 2025

    Patient Satisfaction with a New Patient Video Triage Program

    Adam Dore1 and Yue Yin2, 1Allegheny Health Network, Pittsburgh, PA, 2Allegheny Health Network, Pittsburgh

    Background/Purpose: To assist with lowering new rheumatology patient appointment wait times, our division initiated a New Patient Video Triage Program in 2023. In this program,…
  • Abstract Number: 0138 • ACR Convergence 2025

    Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
  • « Previous Page
  • 1
  • …
  • 57
  • 58
  • 59
  • 60
  • 61
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology